About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum is a company based in Stockholm (Sweden) founded in 1988 was acquired by Advent International in September 2021.. The company has 1,840 employees as of December 31, 2024. Swedish Orphan Biovitrum has completed 4 acquisitions, including Arthrosi Therapeutics, CTI BioPharma and Dova Pharmaceuticals. Swedish Orphan Biovitrum offers products and services including Haemophilia Treatments and ITP Treatments. Swedish Orphan Biovitrum operates in a competitive market with competitors including BridgeBio, Moderna, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.
- Headquarter Stockholm, Sweden
- Employees 1840 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Swedish Orphan Biovitrum Ab
-
Annual Revenue
$3.07 B (USD)8.5as on Dec 31, 2025
-
Net Profit
$51.9 M (USD)-87.7as on Dec 31, 2025
-
EBITDA
$1.97 B (USD)90.23as on Dec 31, 2025
-
Latest Funding Round
$29.64 K (USD), Post-IPO
Oct 31, 2023
-
Investors
Handelsbanken
& 3 more
-
Employee Count
1840
as on Dec 31, 2024
-
Investments & Acquisitions
Arthrosi Therapeutics
& 3 more
-
Acquired by
Advent International
(Sep 02, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Swedish Orphan Biovitrum
Swedish Orphan Biovitrum is a publicly listed company on the OMXSTO with ticker symbol SOBI in Sweden, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Swedish Orphan Biovitrum
Swedish Orphan Biovitrum offers a comprehensive portfolio of products and services, including Haemophilia Treatments and ITP Treatments. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Innovative therapies for blood clotting disorders in rare disease patients
Medications for immune thrombocytopenia and related conditions
Unlock access to complete
Unlock access to complete
Funding Insights of Swedish Orphan Biovitrum
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $29,644
- First Round First Round
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2023 | Amount | Post-IPO - Swedish Orphan Biovitrum | Valuation |
investors |
|
| Sep, 2019 | Amount | Debt – Conventional - Swedish Orphan Biovitrum | Valuation |
investors |
|
| Jun, 2006 | Amount | Post-IPO - Swedish Orphan Biovitrum | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Swedish Orphan Biovitrum
Swedish Orphan Biovitrum has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Handelsbanken, Investor Growth Capital and Advent International. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Corporate-backed venture capital firm focused on fintech, energy, and multiple sectors
|
Founded Year | Domain | Location | |
|
Private equity firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Sovereign wealth is managed and private equity investments are facilitated.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Swedish Orphan Biovitrum
Swedish Orphan Biovitrum has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Arthrosi Therapeutics, CTI BioPharma and Dova Pharmaceuticals. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics for gout, kidney diseases, and oncology are developed.
|
2017 | ||||
|
Drug candidates for rare diseases are acquired, developed, and commercialized.
|
2016 | ||||
|
Healthcare management services are provided by SYNAGIS.
|
1998 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Swedish Orphan Biovitrum
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Swedish Orphan Biovitrum Comparisons
Competitors of Swedish Orphan Biovitrum
Swedish Orphan Biovitrum operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Moderna, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapies for rare and orphan diseases
|
|
| domain | founded_year | HQ Location |
Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Swedish Orphan Biovitrum
Frequently Asked Questions about Swedish Orphan Biovitrum
When was Swedish Orphan Biovitrum founded?
Swedish Orphan Biovitrum was founded in 1988 and raised its 1st funding round 18 years after it was founded.
Where is Swedish Orphan Biovitrum located?
Swedish Orphan Biovitrum is headquartered in Stockholm, Sweden.
Who is the current CEO of Swedish Orphan Biovitrum?
Guido Oelkers is the current CEO of Swedish Orphan Biovitrum.
How many employees does Swedish Orphan Biovitrum have?
As of Dec 31, 2024, the latest employee count at Swedish Orphan Biovitrum is 1,840.
What is the annual revenue of Swedish Orphan Biovitrum?
Annual revenue of Swedish Orphan Biovitrum is $3.07B as on Dec 31, 2025.
What does Swedish Orphan Biovitrum do?
Founded in 1988 and based in Stockholm, Sweden, Swedish Orphan Biovitrum operates as a biopharmaceutical company focused on treatments for rare diseases such as haemophilia, inflammation, and genetic conditions. Lead products include ELOCTA for haemophilia A and ALPROLIX for haemophilia B. Pipeline candidates encompass therapies for tyrosinaemia and alkaptonuria under regulatory review, alongside enzyme replacement options in pre-clinical stages.
Who are the top competitors of Swedish Orphan Biovitrum?
Swedish Orphan Biovitrum's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Swedish Orphan Biovitrum offer?
Swedish Orphan Biovitrum offers Haemophilia Treatments and ITP Treatments.
Is Swedish Orphan Biovitrum publicly traded?
Yes, Swedish Orphan Biovitrum is publicly traded on OMXSTO under the ticker symbol SOBI.
How many acquisitions has Swedish Orphan Biovitrum made?
Swedish Orphan Biovitrum has made 4 acquisitions, including Arthrosi Therapeutics, CTI BioPharma, and Dova Pharmaceuticals.
Who are Swedish Orphan Biovitrum's investors?
Swedish Orphan Biovitrum has 4 investors. Key investors include Handelsbanken, Investor Growth Capital, Advent International, and GIC.
What is Swedish Orphan Biovitrum's ticker symbol?
The ticker symbol of Swedish Orphan Biovitrum is SOBI on OMXSTO.